Michael Mish

Michael Mish is the Director of Medicinal Chemistry at Gilead Sciences, where they manage a team of PhD and MS level research scientists. Previously, they served in various roles at Gilead Sciences, including Senior Research Scientist II, where they led cross-functional discovery research teams and optimized pre-clinical lead series for HIV and HCV antiviral programs. Michael is a co-inventor of several significant drug candidates, including selective TLR8 agonist Selgantolimod, now in Phase 2 clinical trials. They hold a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the California Institute of Technology and completed a postdoctoral research program in organic synthesis at UC Irvine.